Dainippon Sumitomo raises profit guidance despite generally weak first quarter
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) has raised its profit forecasts for the fiscal year ending next 31 March, although the changes are due mainly to delayed marketing expenses and currency effects rather than higher sales.